Teva notches FDA approval for new leukemia drug

The FDA has now stamped approvals on two new drugs for chronic myelogenous leukemia (CML) in as many months. Teva Pharmaceutical's ($TEVA) Synribo won a nod from the agency for treating CML patients whose cancer has persisted after taking two or more previous tyrosine kinase inhibitors (TKIs), Reuters reported. In September, the U.S. regulator gave the green light to Pfizer ($PFE) to sell its CML drug Bosulif, giving patients a new option beyond existing TKIs such as Novartis's ($NVS) Gleevec and Bristol-Myers Squibb's ($BMY) Sprycel. Right around the corner, Ariad Pharmaceuticals ($ARIA) is hoping to gain an OK for its promising leukemia drug ponatinib, which is under review at the FDA with a March 27 action date for regulators to decide on approval. Article



Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.